Wockhardt shares rise 10% after Zaynich aids successful liver transplant trial

Wockhardt shares climbed as much as 8.6% on Monday to Rs 1,517 after the company's experimental antibiotic, Zaynich, enabled a US cancer patient to undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens.

The pharmaceutical company said in an exchange filing, that Zaynich effectively treated a 73-year-old US patient with bile duct cancer who was suffering from chronic bile duct infections caused by extensively drug-resistant pathogens. The treatment enabled the patient to undergo a successful liver transplant and resume chemotherapy.

This is the latest development in a series of compassionate use cases where Zaynich has been deployed to treat life-threatening Gram-negative infections, the company said, adding that to date, 45 patients have benefited from this investigational drug under such programs.


Zaynich is Wockhardt’s proprietary antibiotic targeting multi-drug resistant gram-negative infections. The drug is currently nearing the completion of Phase III trials, which are expected to support its global registration and marketing authorization.

Earlier clinical pharmacology studies were conducted in the United States, and additional trials are ongoing in India for the treatment of carbapenem-resistant infections.

The company has a portfolio of six products at various stages of clinical development and commercialization, each granted Qualified Infectious Disease Product status by the US FDA.

Also read | Bharti Airtel, HDFC Bank among top 26 stocks to watch in 2025: ICICI Securities

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)